Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
61.6M
-
Shares change
-
+463K
-
Total reported value, excl. options
-
$236M
-
Value change
-
-$4.76M
-
Put/Call ratio
-
1.74
-
Number of buys
-
66
-
Number of sells
-
-32
-
Price
-
$3.84
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q2 2019
120 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2019.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.6M shares
of 123M outstanding shares and own 49.97% of the company stock.
Largest 10 shareholders include Consonance Capital Management LP (17.9M shares), BlackRock Inc. (8.08M shares), ARMISTICE CAPITAL, LLC (5M shares), VANGUARD GROUP INC (4.86M shares), MANGROVE PARTNERS (3.84M shares), Broadfin Capital, LLC (2.77M shares), BAKER BROS. ADVISORS LP (2.56M shares), MORGAN STANLEY (2.52M shares), STATE STREET CORP (1.82M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.4M shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.